IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
1 . A method for treating a disorder associated with P2X3 activity in an animal, wherein the disorder associated with P2X3 activity is selected from the group consisting of multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, endometriosis, depression, anxiety, a stress-related disorder, and drug addiction, and wherein the method comprises administering to the animal a therapeutically effective amount of a pharmaceutically active compound of Formula (I) or a salt thereof, wherein the compound of Formula (I) is:
R 1 is selected from the group consisting of cyano, halogen, methyl, and ethyl;
R 2 is selected from the group consisting of hydrogen, halogen, methyl, and ethyl;
R 3 is selected from the group consisting of halogen, methyl, and ethyl;
R 4 is selected from the group consisting of hydrogen, halogen, methyl, ethyl, and methoxy;
as to R 5 and R 6 ;
R 5 and R 6 are independently selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, and hydroxy-C 1 -C 6 -alkyl; or
R 5 and R 6 , together with the nitrogen to which they are both attached, form a 5- or 6-member heterocycloalkyl, wherein:
the heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, and C 1 -C 4 -alkyl;
R 7 and R 8 are independently selected from the group consisting of hydrogen and C 1 -C 4 -alkyl;
R 9 is selected from the group consisting of C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, C 1 -C 6 -alkyl-C 3 -C 6 -cycloalkyl, halo-C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, halo-C 1 -C 6 -alkoxy, and C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl; and
X is selected from a bond, CH 2 , and O.
2 . The method of claim 1 , wherein R 1 is methyl and R 2 is hydrogen.
3 . The method of claim 1 , wherein R 3 and R 4 are fluoro.
4 . The method of claim 1 , wherein X is O.
5 . The method of claim 1 , wherein the compound corresponds in structure to:
and
R 4 is selected from the group consisting of halogen, methyl, and ethyl.
6 . The method of claim 1 , wherein R 5 is hydrogen and R 6 is C 1 -C 6 -alkyl.
7 . The method of claim 1 , wherein R 6 is methyl.
8 . The method of claim 1 , wherein R 7 and R 8 are hydrogen.
9 . The method of claim 1 , wherein R 9 is C 1 -C 6 -alkoxy.
10 . The method of claim 1 , wherein R 9 is methoxy.
11 . The method of claim 1 , wherein the compound corresponds in structure to:
12 . The method of claim 1 , wherein the compound corresponds in structure to:
13 . The method of claim 1 , wherein the compound corresponds in structure to:
14 . The method of claim 1 , wherein the compound corresponds in structure to:
15 . The method of claim 1 , wherein the animal is a mammal.
16 . The method of claim 15 , wherein the mammal is a human.
17 . The method of claim 1 , wherein the disorder associated with P2X3 activity is endometriosis.
18 . The method of claim 13 , wherein the disorder associated with P2X3 activity is endometriosis.
19 . The method of claim 14 , wherein the disorder associated with P2X3 activity is endometriosis.
20 . The method of claim 1 , wherein the method further comprises administering a second pharmaceutically active compound.
21 . The method of claim 13 , wherein the method further comprises administering a second pharmaceutically active compound.
22 . The method of claim 14 , wherein the method further comprises administering a second pharmaceutically active compound.